SCHEMBL2857262

SCHEMBL2857262

Cc1ccc(F)cc1C(=O)NCC1(Cc2ccccc2)CCCCC1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 5/20 0.44
SLC6A9 P48067 1/20 0.43
HCN1 O60741 2/20 0.43
HTT P42858 1/20 0.42
NPFFR1 Q9GZQ6 1/20 0.41
NPFFR2 Q9Y5X5 1/20 0.41
ALDH1A1 P00352 3/20 0.40
THRB P10828 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
LMNA P02545 1/20 0.40
HCN4 Q9Y3Q4 1/20 0.39
PARP1 P09874 1/20 0.39
HDAC4 P56524 1/20 0.39
HSD11B1 P28845 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857884 0.86 ALDH1A1 (0.44) SLC6A9NPFFR1NPFFR2ALDH1A1MEN1
SCHEMBL2861435 0.83 SLC6A9 (0.44) P2RX7SLC6A9NPFFR1NPFFR2ALDH1A1
SCHEMBL5355428 0.81 NPFFR1 (0.44) P2RX7NPFFR1NPFFR2ALDH1A1THRB
SCHEMBL2856026 0.78 MEN1 (0.65) P2RX7HCN1ALDH1A1THRBMEN1
SCHEMBL2858583 0.78 P2RX7 (0.46) P2RX7HCN1HTTNPFFR1NPFFR2
SCHEMBL2861616 0.77 LMNA (0.58) P2RX7SLC6A9NPFFR1NPFFR2ALDH1A1
SCHEMBL2861400 0.76 NPC1 (0.53) SLC6A9NPFFR1NPFFR2ALDH1A1LMNA
SCHEMBL2853482 0.76 MEN1 (0.55) SLC6A9NPFFR1NPFFR2ALDH1A1MEN1
SCHEMBL5351381 0.76 ALDH1A1 (0.45) NPFFR1NPFFR2ALDH1A1LMNAHSD11B1
SCHEMBL2856050 0.76 SLC6A9 (0.52) P2RX7SLC6A9NPFFR1NPFFR2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed
EP-2253328-A1 Cycloalkyl inhibitors of potassium channel function Bristol-Myers Squibb Company (US) 2010-11-24 EP disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION BRISTOL-MYERS SQUIBB COMPANY 2007-06-21 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-7202253-B2 Cycloalkyl inhibitors of potassium channel function BRISTOL-MYERS SQUIBB COMPANY (US) 2007-04-10 US disclosed
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function LLOYD JOHN 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234106-A1 Cycloalkyl inhibitors of potassium channel function KCNJ2, KCNN3, KCNQ5 P2RX7 930/4885SLC6A9 1701/4885HCN1 58/4885
US-20070142333-A1 CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION KCNJ2, KCNN3, KCNQ5 P2RX7 930/4885SLC6A9 1701/4885HCN1 58/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.